Regorafenib active in metastatic GI stromal tumors - medicalxpress.com

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according to a study published ...

A Few Thoughts On The actual Near Future For Doxorubicin - 1UP.COM

TKI to the other, either with sorafenib followed by sunitinib SoSu or sunitinib followed by sorafenib SuSo. Everolimus was associatedwith a median PFS of . months in the in general inhabitants versus . months for placebo hazard ratio HR . self confidence ...

Pfizer Provides Topline Results From Phase 3 Study Of Torisel(R) As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) - Marketwatch

The combination of TORISEL and sunitinib resulted in dose-limiting toxicity (Grade 3/4 erythematous maculopapular rash, and gout/cellulitis requiring hospitalization). For more information on TORISEL, including full prescribing information for ...

AB SCIENCE : Recruitment of the First Patient for the Phase 3 Study on Gleevec®-Resistant GIST, Comparing Masitinib with Sunitinib - 4-traders (press release)

AB Science SA (Euronext Paris - FR0010557264 - AB)(Paris:AB), a pharmaceutical company specialized in research, development and commercialization of protein kinase inhibitors (PKI), announces today the recruitment of the first patient in a phase 3 study ...

Pfizer does not meet primary endpoint in TORISEL Phase 3 study for advanced RCC - News-Medical.Net

Pfizer Inc. announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL ® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT ® (sunitinib malate) therapy ...

Pfizer Reports Results From Phase 3 Study Of Torisel - Quick Facts - RTT News

(RTTNews) - Pfizer Inc (PFE: News ) announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL (temsirolimus) in patients with advanced renal cell carcinoma or RCC whose disease had progressed on or after SUTENT (sunitinib malate) therapy ...

Hot Stock Research for Pfizer, PepsiCo, Duke Energy, Regions Financial, Peabody Energy, and Renren - Sacramento Bee

in patients with advanced renal cell carcinoma or RCC whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not achieve the primary endpoint of prolonging progression free survival or PFS when compared to sorafenib.

Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of Clinical Oncology Annual Meeting - CNBC

Regorafenib Randomized Phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU) - GRID trial Dr. George D.

Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At 2012 ASCO Annual Meeting - Yahoo Finance

Phase 1b safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (ang-2), with sunitinib (Poster discussion, Abstract #3032, June 2) Pharmacokinetic modeling and simulation (PK M&S) supported dose ...

Neuroendocrine Carcinoma Therapeutics Research at Biotech Benchmark - PR Inside

The high growth is primarily attributed to the advent of approved drugs, Sutent (sunitinib) and Afinitor (everolimus), in the major markets. The expected launch of promising drugs in the forecast period will drive the market. The promising drugs to be ...